Apselan Plus 200mg + 30mg 20 caps.

ACTION: The drug has analgesic, anti-inflammatory, and antipyretic effects. It reduces swelling and congestion of the nasal mucosa and the amount of secretions. Unblocks the nose and paranasal sinuses.

INDICATIONS: Occasional use to relieve the symptoms of nasal and sinus congestion accompanied by headache, pain associated with sinus congestion, and fever associated with the flu or cold.

DOSAGE: For oral administration and short-term use. Adults and adolescents over 15 years of age: 1 to 2 tablets orally every 4-6 hours after meals. Do not take more than 6 tablets per day (maximum daily dose of 1200 mg of ibuprofen and 180 mg of pseudoephedrine hydrochloride in divided doses).

Children Apselan Plus is contraindicated for use in children under 15 years of age.

COMPOSITION: 1 tablet contains 200 mg of ibuprofen (Ibuprofenum) + 30 mg of pseudoephedrine hydrochloride (Pseudoephedrini hydrochloridum).

Excipients: Tablet core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silica, anhydrous magnesium stearate. Coating: lactose monohydrate, hypromellose 6cp, titanium dioxide (E 171), macrogol 6000.

CONTRAINDICATIONS:
Hypersensitivity to ibuprofen, pseudoephedrine or any of the excipients.
In patients with hypersensitivity to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs) or in patients with a history of hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) during treatment with ibuprofen, acetylsalicylic acid or other NSAIDs.
History of gastrointestinal bleeding or perforation related to previous NSAID use.
Active or recurrent peptic ulcer or bleeding (confirmed two or more distinct episodes of ulceration or bleeding).
In patients with pheochromocytoma, angle-closure glaucoma, diabetes or thyroid disease.
Hemorrhagic diathesis. –
Severe liver failure, severe renal failure or severe heart failure (NYHA class IV).
Pregnancy or breastfeeding. –
Severe cardiovascular disorders, tachycardia, hypertension, angina pectoris, tachycardia.
Urinary retention. –
In patients taking other NSAIDs, including selective COX-2 inhibitors, pain relievers or nasal decongestants.
In patients taking tricyclic antidepressants. –
In patients receiving, or who have received within the last two weeks, monoamine oxidase inhibitors (MAOIs).
Hyperthyroidism.
Narrow-angle glaucoma.
History of hemorrhagic stroke or presence of risk factors that may increase the risk of hemorrhagic stroke, for example, vasoconstrictor drugs or other oral or nasal decongestants.
Do not use in children and adolescents under 15 years of age.
WARNINGS: Avoid concomitant use of Apselan Plus with other NSAIDs, including selective COX-2 inhibitors.
Adverse effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see gastrointestinal bleeding and cardiovascular risk below).
If symptoms worsen, last longer than 3 days, or other symptoms unrelated to the initial condition occur, treatment should be discontinued unless otherwise directed by a doctor.
Elderly: An increased frequency of adverse reactions has been reported with NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal.
Gastrointestinal bleeding, ulceration and perforation: Gastrointestinal bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events.
The risk of GI bleeding, ulceration, or perforation increases with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with bleeding or perforation, and in the elderly. These patients should be started on the lowest possible dose. In these patients, and also in patients requiring concomitant low-dose aspirin or other drugs that may increase the risk of GI bleeding, combination therapy with protective agents (e.g., misoprostol or proton pump inhibitors) should be considered.
Patients with a history of gastrointestinal bleeding, especially when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding), especially in the initial phase of treatment.
Caution should be exercised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid.
Apselan Plus should be discontinued if gastrointestinal bleeding or ulceration occurs.
NSAIDs should be used with caution in patients with gastrointestinal disease (e.g. ulcerative colitis and Crohn’s disease) as their condition may be exacerbated.
Caution should be exercised in patients with impaired cardiac or renal function, as the use of NSAIDs may result in deterioration of renal function.
Cardiovascular and cerebrovascular system: Clinical studies suggest that use of some NSAIDs (ibuprofen), particularly at a high dose (2400 mg/day), may be associated with a small increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low doses of ibuprofen (e.g. ≤1200 mg/day) are associated with an increased risk of arterial thrombotic events. In patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischemic heart disease, peripheral vascular disease, and/or cerebrovascular disease, ibuprofen treatment should only be considered after careful consideration and high doses (2400 mg/day) should be avoided. Long-term treatment should also be carefully considered in patients with risk factors for cardiovascular events (hypertension, hyperlipidemia, diabetes and smoking), particularly if high doses of ibuprofen (2400 mg/day) are required.
A warning (by the doctor or pharmacist) is necessary before starting treatment in patients with a history of arrhythmia, myocardial infarction, hypertension and/or heart failure, as fluid retention, hypertension and edema have been reported in association with NSAID treatment.
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients are at risk of these reactions early in treatment, particularly during the first month of treatment. Apselan Plus should be discontinued if skin rash, mucosal lesions, or any other signs of hypersensitivity appear.
Severe skin reactions, such as acute generalized exanthematous pustulosis (AGEP), may occur after the use of pseudoephedrine-containing products. Exanthematous pustulosis may occur within the first 2 days of treatment, accompanied by fever and numerous small, usually non-vesicular pustules appearing on swollen, erythematous lesions and primarily located in skin flexures, on the trunk, and on the upper extremities. Patients should be monitored closely. If symptoms such as fever, erythema, or the appearance of numerous small pustules occur, ZATOTABS should be discontinued and appropriate treatment initiated if necessary.
Systemic lupus erythematosus and mixed connective tissue disease increased risk of aseptic meningitis.
Because NSAIDs may interfere with platelet function, they should be used with caution in patients with intracranial bleeding and bleeding diathesis.
Patients with asthma, hypertension, heart disease, diabetes, cirrhosis, kidney failure, thyroid disease or prostatic hyperplasia should consult a physician before using this product.
There is a risk of deterioration of renal function in dehydrated adolescent patients.
Simultaneous, long-term use of various painkillers may lead to kidney damage with the risk of kidney failure (resolute nephropathy).
In patients with active or history of bronchial asthma and allergic diseases due to the possibility of bronchospasm.
The use of NSAIDs may impair female fertility. There is limited evidence that drugs that inhibit cyclooxygenase/prostaglandin synthesis may impair female fertility by affecting ovulation. This effect is reversible and disappears upon discontinuation of the drug.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
Alcohol consumption should be avoided while using the medicinal product.
Pseudoephedrine hydrochloride may result in a positive doping test.
As with other drugs that stimulate the central nervous system, pseudoephedrine has a potential for abuse. Toxic effects may occur at higher doses. Long-term use may lead to tachyphylaxis and an increased risk of overdose. Depression may occur upon abrupt discontinuation of treatment.
Before use, read the leaflet enclosed in the package or consult your doctor or pharmacist, as any preparation used improperly may pose a threat to your life or health.

Buy Apselan Plus 200mg + 30mg 20 caps.
Price of Apselan Plus 200mg + 30mg 20 caps.
Acheter Apselan Plus 200mg + 30mg 20 caps.
Prix de Apselan Plus 200mg + 30mg 20 caps.
Comprar Apselan Plus 200mg + 30mg 20 caps.
Precio de Apselan Plus 200mg + 30mg 20 caps.